肝素结合膨体聚四氟乙烯人工血管膝上股腘旁路多中心注册研究结果
该多中心回顾性注册研究纳入7家意大利血管中心14年间1401例接受肝素结合膨体聚四氟乙烯(HB-ePTFE)人工血管干预的外周动脉阻塞性疾病患者,事后分析其中364例(25.9%)膝上股腘旁路(AKb)患者。围手术期死亡0.8%,早期血栓1.6%,5年一期通畅率64%、二期通畅率74.5%、保肢率95%。结论认为HB-ePTFE人工血管AKb仍是有效选择,围手术期并发症低且长期结果满意。
要点
- HB-ePTFE人工血管膝上股腘旁路围手术期死亡0.8%、早期血栓1.6%。
- 5年一期通畅率64%、二期通畅率74.5%、保肢率95%。
- 在腔内治疗时代,HB-ePTFE旁路仍是长段或复杂病变的有效选择。
核心结论
- 在腔内治疗热情高涨、长段或复杂股浅动脉病变治疗结果存在争议的时代,使用HB-ePTFE人工血管行膝上股腘旁路仍是有效选择,围手术期并发症发生率低且长期结果满意。
研究设计与样本
- 多中心回顾性注册研究,涉及7家意大利血管中心,14年期间(截至2016年3月)共1401例因外周动脉阻塞性疾病使用HB-ePTFE人工血管的干预。
- 事后分析识别出364例(25.9%)接受膝上股腘旁路(AKb)的患者。
主要发现
- 61例(16.7%)患者AKb是在同侧既往血运重建失败后进行的。
- 164例(45%)存在危重肢体缺血,其余患者为限制生活的间歇性跛行。
- 围手术期死亡3例(0.8%):院内2例死于急性心肌梗死,出院后1例死于致死性心律失常。
- 早期血栓6例(1.6%),均为因危重肢体缺血行初次AKb的患者。
- 围手术期截肢累积率0.5%(2例),早期再干预累积率3%(11例)。
临床怎么用
- 对于长段或复杂股浅动脉病变,在腔内治疗结果存在争议时,HB-ePTFE人工血管膝上股腘旁路可作为有效的外科选择。
- 该术式围手术期并发症发生率低,长期通畅率和保肢率满意,可用于危重肢体缺血和限制生活的间歇性跛行患者。
局限性
- 本研究为回顾性注册研究,事后分析仅纳入364例AKb患者,可能存在选择偏倚。
- 随访中位时间28个月,部分患者随访时间较短,长期结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to retrospectively analyze early and follow-up results of above-the-knee femoropopliteal bypasses (AKb) performed with a bioactive heparin-bonded expanded polytetrafluoroethylene (HB-ePTFE) graft in patients with peripheral arterial obstructive disease in a multicentric retrospective registry involving seven Italian vascular centers. METHODS: During a 14-year period ending in March 2016, an HB-ePTFE graft was used in 1401 interventions performed for peripheral arterial obstructive disease. Comorbidities, risk factors, and follow-up outcomes were collected in a multicenter registry with a dedicated database. A post hoc analysis of the database was performed to identify 364 (25.9%) patients who underwent AKb. Early (intraoperative and <30 days) results were analyzed in terms of death, thrombosis, amputations, reinterventions, and the occurrence of major local and systemic complications. Follow-up results were analyzed by life-table analysis (Kaplan-Meier test) in terms of primary and secondary graft patency, assisted primary patency, limb preservation, and amputation-free survival. The analysis of follow-up results was stopped in December 2016. RESULTS: In 61 (16.7%) patients, AKb was performed after the failure of a previous ipsilateral revascularization. Critical limb ischemia was present in 164 (45%) cases; the remaining patients had life-limiting intermittent claudication. Perioperative mortality occurred in three (0.8%) patients: in the hospital (n = 2) due to acute myocardial infarction and after discharge (n = 1) due to fatal arrhythmia. Early thromboses occurred in six (1.6%) patients; all these patients had primary AKb for critical limb ischemia. The cumulative rate of perioperative amputations was 0.5% (2 cases), whereas the cumulative rate of early reinterventions was 3% (11 cases). Median duration of follow-up was 28 months (range, 1-168 months); the median cumulative follow-up index for survival was 0.75 (range, 0.05-1). Estimated survival at 5 years was 75.3% (standard error [SE], 0.03). Estimated 5-year primary patency was 64% (SE, 0.04); the corresponding figure in terms of assisted primary patency was 65% (SE, 0.035). Secondary patency rate at 5 years was 74.5% (SE, 0.03). The rate of limb preservation at 5 years was 95% (SE, 0.02); the corresponding figure in terms of amputation-free survival was 74% (SE, 0.04). CONCLUSIONS: In an era of endovascular enthusiasm, with conflicting results for the treatment of long or complex lesions of the superficial femoral artery, AKb with the use of HB-ePTFE graft remains an effective option, with low rate of perioperative complications and satisfactory long-term results.
引用
- Piffaretti G, Dorigo W, Castelli P, et al. Results from a multicenter registry of heparin-bonded expanded polytetrafluoroethylene graft for above-the-knee femoropopliteal bypass. J Vasc Surg. 2017. PMID: 29175037. doi:10.1016/j.jvs.2017.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。